Sign In
Buy PFE
$26.04
+0.350 (+1.36%)
At Close: Jun 05, 2026
Pfizer to offer drugs at not-for-profit prices in low income countries
10:50am, Thursday, 26'th May 2022 Quartz
Pfizer, one of the world’s leading pharmaceutical companies, has announced that it will be providing nearly two dozen of its patented products at not-for-profit prices to 45 lower-income countries,
Better Dividend Stock: Pfizer or Merck?
10:04am, Thursday, 26'th May 2022 The Motley Fool
It's a close call between these two big drugmakers.
How Vaccine Cash Could Fuel Pfizer's Future Growth
03:33pm, Wednesday, 25'th May 2022 The Motley Fool
The drugmaker has a bold strategy to transform itself by 2030.
CDC: A Paxlovid rebound may be ‘natural’ part of a COVID-19 infection
02:45pm, Wednesday, 25'th May 2022 MarketWatch
The public-health agency continues to recommend the antiviral.
I wrongly expected COVID to fade last summer — here’s what to expect this time
02:24pm, Wednesday, 25'th May 2022 MarketWatch
We are in better shape than we were at this time last year, but we are nowhere close to having COVID under control.
Here’s the signal for investors from the deep pessimism of Bill Ackman and George Soros
02:07pm, Wednesday, 25'th May 2022 MarketWatch
An abundance of negativity out there may have created a short-term bottom for stocks, says our call of the day.
Pfizer (PFE) Reports More Positive Data From Etrasimod Study
12:41pm, Wednesday, 25'th May 2022 Zacks Investment Research
Pfizer (PFE) states that data from the ELEVATE 12 and ELEVATE 52 studies will form the basis of the regulatory submissions on etrasimod expected later this year
Better Buy Ahead of FDA Meetings: Moderna vs. Novavax
10:00am, Wednesday, 25'th May 2022 The Motley Fool
June may be a critical month for both companies.
3 Recession-Proof Stocks To Protect Your Portfolio From Fed-Induced Turmoil
09:38am, Wednesday, 25'th May 2022 Investing.com
AstraZeneca (AZN) Gets EU Nod for COVID-19 Booster Shot
06:48pm, Tuesday, 24'th May 2022 Zacks Investment Research
AstraZeneca's (AZN) third/booster dose of its COVID-19 vaccine gets authorized in Europe for use in adults, both for homologous and heterologous use.
FDA panel to review Pfizer and Moderna vaccines for children aged six month to 4 years on June 15
06:05pm, Tuesday, 24'th May 2022 MarketWatch
The Food and Drug Administration said Monday an advisory panel would meet June 15 to discuss use of the vaccines developed by Pfizer and German partner BioNTech, as well as the one developed by Modern
Ocugen (OCGN) Covaxin Studies Clinical Hold Lifted by FDA
03:30pm, Tuesday, 24'th May 2022 Zacks Investment Research
Ocugen (OCGN) gets respite after the FDA lifts the clinical hold on the company's phase II/III study, OCU-002, for Covaxin (BBV152).
Biohaven's (BHVN) Zavegepant NDA for Migraine Accepted by FDA
01:47pm, Tuesday, 24'th May 2022 Zacks Investment Research
The FDA accepts Biohaven's (BHVN) NDA seeking approval for its pipeline candidate, zavegepant, as an intra-nasal treatment for migraine. A decision is expected early next year.
Pfizer & BioNTech COVID Jab Booster Effective in Kids Under 5
01:26pm, Tuesday, 24'th May 2022 Zacks Investment Research
Pfizer (PFE) and BioNTech (BNTX) state that their three-dose COVID-19 vaccine is 80% effective in children under five years of age.
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
01:00pm, Tuesday, 24'th May 2022 Zacks Investment Research
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
